Acute Infusion Pain Reaction Due to Anti‐PD‐1 Antibodies for the Treatment of Cutaneous Squamous Cell Carcinoma in Recessive Dystrophic Epidermolysis Bullosa: A Case Report and Review of the Literature

Documenti analoghi

• Narrowing the Differential: A Unique Case of Dystrophic Epidermolysis Bullosa
  di: Lauren Yacobucci, et al.
  Pubblicazione: (2025)
• Urothelial Carcinoma of the Penile Urethra as a Potential Secondary Complication of Junctional Epidermolysis Bullosa: A Case Report and Review of the Literature
  di: Jessica McClatchy, et al.
  Pubblicazione: (2026)
• Off‐Label Use of Double‐Dose Beremagene Geperpavec (B‐ VEC ) in the Treatment of Recessive Dystrophic Epidermolysis Bullosa: A Promising Clinical Case
  di: Melissa M. Yamada, et al.
  Pubblicazione: (2025)
• The Clinical Efficacy and Safety of Dupilumab Monotherapy in Dystrophic Epidermolysis Bullosa: A Retrospective Real‐World Study
  di: Jian-Bo Wang, et al.
  Pubblicazione: (2026)
• Porous Silicon Nanoneedles Efficiently Deliver Adenine Base Editor to Correct a Recurrent Pathogenic COL7A1 Variant in Recessive Dystrophic Epidermolysis Bullosa
  di: Salman Ahmad Mustfa, et al.
  Pubblicazione: (2025)